Compare RVYL & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RVYL | ICU |
|---|---|---|
| Founded | 2007 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5M | 9.1M |
| IPO Year | 2008 | N/A |
| Metric | RVYL | ICU |
|---|---|---|
| Price | $7.81 | $3.07 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 16.4K | ★ 70.7K |
| Earning Date | 04-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,131,000.00 | N/A |
| Revenue This Year | $770.54 | $53.00 |
| Revenue Next Year | N/A | $50.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.14 | $0.22 |
| 52 Week High | $8.55 | $5.10 |
| Indicator | RVYL | ICU |
|---|---|---|
| Relative Strength Index (RSI) | 67.46 | 30.23 |
| Support Level | $5.00 | $2.26 |
| Resistance Level | $8.55 | $4.96 |
| Average True Range (ATR) | 0.65 | 0.28 |
| MACD | 0.11 | -0.11 |
| Stochastic Oscillator | 96.06 | 2.66 |
Ryvyl Inc is a financial technology company that provides payment acceptance and disbursement solutions, mainly enabling merchants to process credit card transactions through BIN sponsorship arrangements with acquiring banks and payment processors, where it operates as an intermediary performing functions such as merchant underwriting, onboarding, risk monitoring, and customer support. The company also offers its internally developed NEMS Core platform, which facilitates automated inbound and outbound disbursements through a modular workflow system.
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.